Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 4 Apr 2014 |
| Zealand announces the grant of warrants to its Chief Scientific Officer under existing incentive scheme | 1 Apr 2014 |
| Zealand Pharma A/S announces Full Year results and publication of the Annual Report for 2013 | 20 Mar 2014 |
| Notice of release date and conference call for Zealand’s Full Year results and Annual Report for 2013 | 12 Mar 2014 |
| Zealand to present at upcoming Credit Suisse 2014 London Healthcare Conference | 20 Feb 2014 |